Chronic Kidney Disease in Children Prospective Cohort Study (CKiD)
Chronic Kidney DiseaseThe Division of Kidney, Urologic, and Hematologic Diseases (DKUHD) of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), in collaboration with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) and the National Heart, Lung and Blood Institute (NHLBI) funded a cooperative agreement including two Clinical Coordinating Centers (at Children's Hospital of Philadelphia and at Children's Mercy Hospital in Kansas City), a central biochemistry laboratory (at the University of Rochester) and a Data Coordinating Center (at Johns Hopkins School of Public Health) to conduct a prospective epidemiological study of children with chronic kidney disease (CKD).
ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects...
Chronic Kidney DiseaseEnd Stage Renal Disease9 moreThe purpose of this study is to evaluate whether cinacalcet + low dose vitamin D attenuates the progression of vascular calcification over one year, compared with a treatment regimen that includes flexible vitamin D dosing in the absence of cinacalcet, in subjects with chronic kidney disease receiving hemodialysis
Transplant and Addiction Project (TAP) - 1
End Stage Liver DiseaseEnd Stage Renal Disease1 moreThe purpose of this study is to test a novel distance-based (telephone) intervention to help transplant candidates with current or recent substance abuse to stay "clean and sober" both prior and following transplant surgery.
Aranesp® Monthly Preference Study - 2
Kidney DiseaseThe purpose of this study was to evaluate subject preference for Aranesp® administered once monthly (i.e., every 4 weeks (Q4W)) or Procrit® administered once weekly (QW).
Burden of Chronic Kidney Disease (CKD), Type 2 Diabetes Mellitus (T2DM), and Comorbid T2DM/CKD in...
Chronic Kidney DiseasesType 2 DiabetesThe purpose of the research study is to describe the burden of disease among three different cohorts of patients: (1) patients diagnosed with CKD, (2) those with T2DM; and (3) those with T2DM and comorbid CKD.
DKK3 for Prognosis and Monitoring of GFR Loss in Heart Failure
Heart FailureChronic Kidney DiseasesThe individual course of chronic kidney disease (CKD) may vary, and improved methods for identifying which patients will experience estimated glomerular filtration rate (eGFR) loss are needed. Recently, urinary dickkopf-3 (DKK3) has been proposed to predict eGFR loss in patients with CKD, independent of presence of albuminuria. The investigators sought to examine the association between DKK3 and loss of eGFR in patients with heart failure (HF). The investigators hypothesized that changes in DKK3 under treatment may be helpful to monitor individual kidney disease course.
Study to Evaluate the Efficacy and Safety of Selonsertib in Participants With Moderate to Advanced...
Diabetic Kidney DiseaseThe primary objective of this study is to evaluate whether selonsertib (SEL) can slow the decline in kidney function in participants with moderate to advanced diabetic kidney disease (DKD).
Optimized vs. Standard Automated Peritoneal Dialysis Regimens Study
End Stage Kidney DiseaseChronic Kidney Disease Requiring Chronic DialysisThis clinical study is designed to evaluate the theoretical prediction of a lower glucose absorption in optimized automated peritoneal dialysis regimes. Patients will receive both a standard 6 x 2L 1.36% glucose regime or an optimized 7 x 2 L 2.27% glucose + 5 x 2 L 0.1% glucose regime in a crossover fashion.
A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Diabetic...
Diabetic NephropathiesThis study is open to adults with diabetic kidney disease. The purpose of the study is to find out whether a medicine called BI 685509 improves kidney function. Three different doses of BI 685509 are tested in this study. Participants get either one of the three doses of BI 685509 or placebo. It is decided by chance who gets which BI 685509 dose and who gets placebo. Participants take BI 685509 or placebo as tablets 3 times a day. Placebo tablets look like BI 685509 tablets but do not contain any medicine. Participants continue taking their usual medicine for diabetes and kidney disease throughout the study. Participants are in the study for about 7 months. During this time, they visit the study site about 11 times. Where possible, about 6 of the 11 visits can be done at the participant's home instead of the study site. The trial staff may also contact the participants by phone or video call. Kidney function is assessed based on the analysis of urine samples, which participants collect at home. At the end of the trial the results are compared between the different doses of BI 685509 and placebo. During the study, the doctors also regularly check the general health of the participants.
Chronic Arterial Disease, Quality of Life and Mortality in Chronic Kidney Injury
Kidney DiseasesCardiovascular DiseasesCADKID-study is a prospective follow-up study assessing arterial disease, quality of life, mortality and their predictors in patients with severe chronic kidney disease.